121 related articles for article (PubMed ID: 26169833)
1. p110α Hot Spot Mutations E545K and H1047R Exert Metabolic Reprogramming Independently of p110α Kinase Activity.
Chaudhari A; Krumlinde D; Lundqvist A; Akyürek LM; Bandaru S; Skålén K; Ståhlman M; Borén J; Wettergren Y; Ejeskär K; Rotter Sopasakis V
Mol Cell Biol; 2015 Oct; 35(19):3258-73. PubMed ID: 26169833
[TBL] [Abstract][Full Text] [Related]
2. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.
Carson JD; Van Aller G; Lehr R; Sinnamon RH; Kirkpatrick RB; Auger KR; Dhanak D; Copeland RA; Gontarek RR; Tummino PJ; Luo L
Biochem J; 2008 Jan; 409(2):519-24. PubMed ID: 17877460
[TBL] [Abstract][Full Text] [Related]
3. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
[TBL] [Abstract][Full Text] [Related]
5. The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer.
Jiang W; He T; Liu S; Zheng Y; Xiang L; Pei X; Wang Z; Yang H
J Hematol Oncol; 2018 Dec; 11(1):139. PubMed ID: 30547809
[TBL] [Abstract][Full Text] [Related]
6. Assessing the subcellular distribution of oncogenic phosphoinositide 3-kinase using microinjection into live cells.
Layton MJ; Rynkiewicz NK; Ivetac I; Horan KA; Mitchell CA; Phillips WA
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919038
[TBL] [Abstract][Full Text] [Related]
7. Functional analysis of PIK3CA gene mutations in human colorectal cancer.
Ikenoue T; Kanai F; Hikiba Y; Obata T; Tanaka Y; Imamura J; Ohta M; Jazag A; Guleng B; Tateishi K; Asaoka Y; Matsumura M; Kawabe T; Omata M
Cancer Res; 2005 Jun; 65(11):4562-7. PubMed ID: 15930273
[TBL] [Abstract][Full Text] [Related]
8. Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation.
Sopasakis VR; Liu P; Suzuki R; Kondo T; Winnay J; Tran TT; Asano T; Smyth G; Sajan MP; Farese RV; Kahn CR; Zhao JJ
Cell Metab; 2010 Mar; 11(3):220-30. PubMed ID: 20197055
[TBL] [Abstract][Full Text] [Related]
9. Novel all-hydrocarbon stapled p110α[E545K] peptides as blockers of the oncogenic p110α[E545K]-IRS1 interaction.
Hu X; He Y; Wu L; Hao Y; Wang Z; Zheng W
Bioorg Med Chem Lett; 2017 Dec; 27(24):5446-5449. PubMed ID: 29138025
[TBL] [Abstract][Full Text] [Related]
10. Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade.
Wang C; Che L; Hu J; Zhang S; Jiang L; Latte G; Demartis MI; Tao J; Gui B; Pilo MG; Ribback S; Dombrowski F; Evert M; Calvisi DF; Chen X
Liver Int; 2016 Aug; 36(8):1176-86. PubMed ID: 26716908
[TBL] [Abstract][Full Text] [Related]
11. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
[TBL] [Abstract][Full Text] [Related]
12. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
Hon WC; Berndt A; Williams RL
Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
[TBL] [Abstract][Full Text] [Related]
13. Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations.
Leontiadou H; Galdadas I; Athanasiou C; Cournia Z
Sci Rep; 2018 Oct; 8(1):15544. PubMed ID: 30341384
[TBL] [Abstract][Full Text] [Related]
14. Hepatic miR-378 targets p110α and controls glucose and lipid homeostasis by modulating hepatic insulin signalling.
Liu W; Cao H; Ye C; Chang C; Lu M; Jing Y; Zhang D; Yao X; Duan Z; Xia H; Wang YC; Jiang J; Liu MF; Yan J; Ying H
Nat Commun; 2014 Dec; 5():5684. PubMed ID: 25471065
[TBL] [Abstract][Full Text] [Related]
15. The Phosphoinosotide 3-Kinase Catalytic Subunit p110α is Required for Normal Lens Growth.
Sellitto C; Li L; Vaghefi E; Donaldson PJ; Lin RZ; White TW
Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3145-51. PubMed ID: 27304846
[TBL] [Abstract][Full Text] [Related]
16. Cancer-specific mutations in PIK3CA are oncogenic in vivo.
Bader AG; Kang S; Vogt PK
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1475-9. PubMed ID: 16432179
[TBL] [Abstract][Full Text] [Related]
17. PI3-kinase p110α mediates β1 integrin-induced Akt activation and membrane protrusion during cell attachment and initial spreading.
Zeller KS; Idevall-Hagren O; Stefansson A; Velling T; Jackson SP; Downward J; Tengholm A; Johansson S
Cell Signal; 2010 Dec; 22(12):1838-48. PubMed ID: 20667469
[TBL] [Abstract][Full Text] [Related]
18. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
Pang H; Flinn R; Patsialou A; Wyckoff J; Roussos ET; Wu H; Pozzuto M; Goswami S; Condeelis JS; Bresnick AR; Segall JE; Backer JM
Cancer Res; 2009 Dec; 69(23):8868-76. PubMed ID: 19903845
[TBL] [Abstract][Full Text] [Related]
19. Biophysical aspect of phosphatidylinositol 3-kinase and role of oncogenic mutants (E542K & E545K).
Kalsi N; Gopalakrishnan C; Rajendran V; Purohit R
J Biomol Struct Dyn; 2016 Dec; 34(12):2711-2721. PubMed ID: 26646651
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly.
Kinross KM; Montgomery KG; Mangiafico SP; Hare LM; Kleinschmidt M; Bywater MJ; Poulton IJ; Vrahnas C; Henneicke H; Malaterre J; Waring PM; Cullinane C; Sims NA; McArthur GA; Andrikopoulos S; Phillips WA
FASEB J; 2015 Apr; 29(4):1426-34. PubMed ID: 25550458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
